Inactive Instrument

Apotheca Biosciences, Inc.

Equities

CBDC

US03836L1070

Biotechnology & Medical Research

Apotheca Biosciences, Inc. Reports Earnings Results for the First Quarter Ended April 30, 2019

June 19, 2019 at 05:31 pm EDT

Apotheca Biosciences, Inc. announced earnings results for the first quarter ended April 30, 2019. For the first quarter, the company announced sales was USD 0. Operating loss was USD 299,080. Net loss was USD 2,671. Basic loss per share was USD 0.01.

Latest news about Apotheca Biosciences, Inc.

Apotheca Biosciences, Inc. cancelled the acquisition of 51% of Hemp Bloom LLC.	20-06-19	CI
Apotheca Biosciences, Inc. Announces Resignation of P.C. Sundareswaran as the Chairman and CEO	19-08-09	CI
Deirdre Fernandes Resigns as VP of Operations and Director of Apotheca Biosciences, Inc	19-07-02	CI
Apotheca Biosciences, Inc. signed a definitive agreement to acquire 51% of Hemp Bloom LLC.	19-06-20	CI
Apotheca Biosciences, Inc. Reports Earnings Results for the First Quarter Ended April 30, 2019	19-06-19	CI
Apotheca Biosciences Introduces XKAPE by ProMED, Newest Product Line Designed for Independent Grocers & Convenience Stores	19-06-18	CI
Apotheca Biosciences, Inc. Announces Resignation of Verghese from Chief Technical Officer and Director	19-05-31	CI
Apotheca Biosciences, Inc. will Change its Ticker to CBDC from PCFP	19-04-04	CI
Apotheca Biosciences Announces the Incorporation of Its Newly Created Subsidiary ProMED Biosciences, Inc	19-04-01	CI
Apotheca Biosciences, Inc. Appoints P.C. Sundar as its Chairman & CEO	19-02-06	CI
Apotheca Biosciences Introduces ProMED	19-01-15	CI
Apotheca Biosciences, Inc. Announces Management Changes	18-12-12	CI
Apotheca Biosciences Signs an LOI For Purchase of Nano Creaciones S.A. P.I. de C.V	18-11-06	CI
Apotheca Biosciences Announces Addition of Dr. Herbert Weissbach to the Cannabis Scientific Advisory Board	18-11-01	CI
Apotheca Biosciences Announces the Addition of Malireddy Srinivasulu Reddy to its Research Team as Chief Medical Advisor	18-10-15	CI
Apotheca Biosciences and CB Scientific Joint Venture to Market Hemp CBD Infused Energy & Chill Drinks Under Brands DAVA & Magic Dragon High	18-10-08	CI
Apotheca Biosciences Inc. Overviews GameDayRx, CBD & Cannabis Tailor-Made for Athletes	18-09-27	CI
Cannabis Leaf, Inc. will Change its Name to Apotheca Biosciences, Inc	18-08-24	CI
Cannabis Leaf Incorporated Announces Board Changes	18-07-11	CI
Apotheca Biosciences, Inc. completed the acquisition of Cannabis Leaf, Inc. in a reverse merger transaction.	18-06-24	CI
Apotheca Biosciences Inc. Announces RAPID Launching	18-06-05	CI
Cannabis Leaf Secures the IP Rights for Pain Patch, Apotheca Biosciences’ Pain Alleviation Technology	18-05-08	CI
Apotheca Biosciences, Inc. entered into an agreement to acquire Cannabis Leaf, Inc. in a reverse merger transaction.	18-03-06	CI
FutureLand, Corp. acquired 20% stake in Apotheca Biosciences, Inc. from CB Scientific, Inc..	17-09-17	CI

Chart Apotheca Biosciences, Inc.

Duration

Period

More charts

Company Profile

Apotheca Biosciences, Inc., formerly Cannabis Leaf Inc., is a medical device company. The Company is developing engineering and device solutions for cannabinoid medical technologies. It is focused on developing medical products and nutraceuticals and formulates and delivers technologies. The Company serves healthcare and consumer care industry. The Company's products include transdermal and sublingual. It also provides nasal delivery technologies for precise and controlled dosing of cannabinoids. Its pipeline products includes, transdermal, sublingual, and nasal delivery technologies.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research